Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full ...
Larimar Therapeutics, Inc. ('Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an ...
Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results